Cymabay Therapeutics Inc logo

CBAY - Cymabay Therapeutics Inc Share Price

$7.24 0.2  2.3%

Last Trade - 30/09/20

Mid Cap
Market Cap £379.2m
Enterprise Value £247.9m
Revenue £n/a
Position in Universe 2949th / 6411
Unlock CBAY Revenue
Relative Strength (%)
1m +20.4%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -4.07%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 10.00 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, CymaBay Therapeutics Inc revenues was not reported. Net loss decreased 49% to $23.8M. Lower net loss reflects Research and Develop decrease of 57% to $16.3M (expense), General and Admin decrease of 23% to $5.9M (expense), Stock-based Compensation in R&D decrease of 47% to $1.1M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.72 to -$0.35.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


CBAY Revenue Unlock CBAY Revenue

Net Income

CBAY Net Income Unlock CBAY Revenue

Normalised EPS

CBAY Normalised EPS Unlock CBAY Revenue

PE Ratio Range

CBAY PE Ratio Range Unlock CBAY Revenue

Dividend Yield Range

CBAY Dividend Yield Range Unlock CBAY Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CBAY EPS Forecasts Unlock CBAY Revenue
Profile Summary

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. Its pipeline includes Seladelpar, MBX-2982 and CB-001. The Company’s lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. The PPARd receptor is a nuclear receptor that regulates genes involved in bile acid/sterol, lipid, and glucose metabolism, and regulation of certain inflammatory cells. Seladelpar focuses on treating certain diseases of the liver and a variety of disorders of lipid metabolism.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated October 5, 1988
Public Since January 16, 2014
No. of Shareholders: 227
No. of Employees: 24
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 68,887,092
Free Float (0.0%)
Eligible for
CBAY Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CBAY
Upcoming Events for CBAY
Frequently Asked Questions for Cymabay Therapeutics Inc
What is the Cymabay Therapeutics Inc share price?

As of 30/09/20, shares in Cymabay Therapeutics Inc are trading at $7.24, giving the company a market capitalisation of £379.2m. This share price information is delayed by 15 minutes.

How has the Cymabay Therapeutics Inc share price performed this year?

Shares in Cymabay Therapeutics Inc are currently trading at $7.24 and the price has moved by 38.28% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cymabay Therapeutics Inc price has moved by 21.31% over the past year.

What are the analyst and broker recommendations for Cymabay Therapeutics Inc?

Of the analysts with advisory recommendations for Cymabay Therapeutics Inc, there are there are currently 5 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Cymabay Therapeutics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Cymabay Therapeutics Inc next release its financial results?

Cymabay Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Cymabay Therapeutics Inc dividend yield?

Cymabay Therapeutics Inc does not currently pay a dividend.

Does Cymabay Therapeutics Inc pay a dividend?

Cymabay Therapeutics Inc does not currently pay a dividend.

When does Cymabay Therapeutics Inc next pay dividends?

Cymabay Therapeutics Inc does not currently pay a dividend.

How do I buy Cymabay Therapeutics Inc shares?

To buy shares in Cymabay Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Cymabay Therapeutics Inc?

Shares in Cymabay Therapeutics Inc are currently trading at $7.24, giving the company a market capitalisation of £379.2m.

Where are Cymabay Therapeutics Inc shares listed? Where are Cymabay Therapeutics Inc shares listed?

Here are the trading details for Cymabay Therapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: CBAY
What kind of share is Cymabay Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Cymabay Therapeutics Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Cymabay Therapeutics Inc share price forecast 2020?

Shares in Cymabay Therapeutics Inc are currently priced at $7.24. At that level they are trading at 80.79% discount to the analyst consensus target price of 0.00.

Analysts covering Cymabay Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.713 for the next financial year.

How can I tell whether the Cymabay Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cymabay Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 0.273k%. At the current price of $7.24, shares in Cymabay Therapeutics Inc are trading at 0.120k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Cymabay Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Cymabay Therapeutics Inc.

Who are the key directors of Cymabay Therapeutics Inc?

Cymabay Therapeutics Inc's management team is headed by:

Charles McWherter - SVP
Sujal Shah - PRE
Robert Wills - CHM
Kurt von Emster - IND
Paul Truex - IND
Caroline Loewy - IND
Daniel Menold - VFN
Klara Dickinson - CCO
Who are the major shareholders of Cymabay Therapeutics Inc?

Here are the top five shareholders of Cymabay Therapeutics Inc based on the size of their shareholding:

Avoro Capital Advisors LLC Investment Advisor/Hedge Fund
Percentage owned: 14.95% (10.3m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 7.43% (5.12m shares)
Foresite Capital Management, LLC Private Equity
Percentage owned: 6.45% (4.44m shares)
Boxer Capital, L.L.C. Hedge Fund
Percentage owned: 5.81% (4.00m shares)
Newtyn Management, LLC Hedge Fund
Percentage owned: 5.38% (3.70m shares)
Similar to CBAY
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.